Key highlights
- 61% of patients in the 600 mg high-dose group achieved PASI 100 at Week 16 vs 0% for placebo
- High-dose secondary endpoints reached 86% for both PASI 90 and IGA 0/1 clearance
- Safety data showed 39% treatment-emergent adverse events in the high-dose group
- Company plans to initiate Phase 3 clinical trials for ORKA-001 in the first half of 2027
- Cash reserves of $1.1 billion expected to fund operations through the BLA filing for ORKA-001
Clinical Efficacy and Safety Results
Oruka Therapeutics reported that its Phase 2b EVERLAST-B trial met its primary endpoint, with 61% of patients in the 600 mg ORKA-001 group achieving PASI 100 at Week 16. The double-blind, placebo-controlled study involved 187 patients with moderate-to-severe plaque psoriasis across sites in the U.S., Canada, and Europe. Secondary efficacy endpoints indicated that 86% of high-dose patients reached PASI 90 and IGA 0/1 scores. Safety data remained consistent with the IL-23p19 inhibitor class, as 39% of patients in the high-dose cohort reported treatment-emergent adverse events compared to 43% in the placebo group.
Upcoming Pipeline Milestones
- Initiation of Phase 3 trials for ORKA-001 in moderate-to-severe psoriasis expected in 1H 2027
- Full 52-week data for the EVERLAST-A Phase 2a trial on track for December 2026
- ORKA-002 16-week results from the ORCA-SURGE Phase 2 trial expected in 1Q 2027
- Ongoing assessment of long-term durability and once-yearly maintenance dosing through Week 100
Up 23.8% since our story on 26 Oct: $80.15 when we broke it → $99.24 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $74.48 |
|---|---|
| 20 Oct | $79.09 |
| 21 Oct | $79.92 |
| 22 Oct | $81.15 |
| 23 Oct | $80.15 |
| 26 Oct | $90.33 |
| 27 Oct | $95.81 |
| 28 Oct | $95.97 |
| 29 Oct | $96.65 |
| 30 Oct | $96.87 |
| 2 Nov | $95.43 |
| 3 Nov | $99.55 |
| 4 Nov | $101.41 |
| 5 Nov | $96.02 |
| 6 Nov | $102.86 |
| 9 Nov | $104.56 |
| 10 Nov | $109.50 |
| 11 Nov | $107.17 |
| 12 Nov | $104.99 |
| 13 Nov | $105.35 |
| 16 Nov | $99.24 |
Clinical Development Significance
“These results further solidify our confidence that ORKA-001 could become the preferred medicine for psoriasis, with high rates of complete skin clearance, a favorable safety profile, and potential for dosing once to twice per year.”
Financial and Industry Context
As a clinical-stage biotechnology firm, Oruka currently maintains no commercial revenue or order backlog. However, the company holds a strong liquidity position following an upsized $700.4 million public offering completed in April 2026. Management has projected that its current cash and marketable securities, totaling approximately $1.1 billion, will be sufficient to fund operations through the eventual Biologics License Application filing for ORKA-001. The company's market capitalization stands at $5.31 billion as it advances a pipeline of half-life extended biologics designed for less frequent maintenance dosing than existing standard-of-care treatments.
| Date | Announcement | Amount |
|---|---|---|
| 23 Sep 2026 | Positive Week 28 results for ORKA-001 from the Phase 2a EVERLAST-A trial in moderate-to-severe plaque psoriasisSource: globenewswire.com | – |
| 10 Aug 2026 | Second quarter 2026 financial results and corporate updateSource: ir.orukatx.com | – |
| 13 May 2026 | First quarter 2026 financial results and corporate updateSource: ir.orukatx.com | – |
| 28 Apr 2026 | Pricing of upsized underwritten public offering of 9,660,000 common sharesSource: ir.orukatx.com | $700.4 Million |
| 27 Apr 2026 | Positive Week 16 interim results for ORKA-001 from the Phase 2a EVERLAST-A trialSource: ir.orukatx.com | – |
Management commentary
“The potential for these effects to be long lasting, with just one or two doses a year, would be a paradigm shift in moderate-to-severe psoriasis management, allowing for the trifecta of clear skin, convenience, and excellent safety that would further elevate the standard of care we can offer our patients.”
| Share price | $80.15 |
|---|---|
| Market cap | $5.3B |
| 1-month price change | -10.88% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Oruka Therapeutics, Inc. announcing Week 16 results from its Phase 2b EVERLAST-B clinical trial.
Track Oruka Therapeutics, Inc. live
Get the next Oruka Therapeutics, Inc. SEC filing seconds after it lands.